vs
J&J SNACK FOODS CORP（JJSF）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
J&J SNACK FOODS CORPの直近四半期売上が大きい（$343.8M vs $177.4M、Pacira BioSciences, Inc.の約1.9倍）。Pacira BioSciences, Inc.の純利益率が高く（1.6% vs 0.3%、差は1.4%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs -5.2%）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（-0.2% vs -2.2%）
J&Jスナックフーズ社は米国の有名なブランドスナック菓子・冷凍飲料の製造・販売・流通業者で、本社はニュージャージー州マウントローレルに所在します。米国44州、メキシコ、カナダに175を超える生産・保管・流通拠点を構え、ナスダックグローバルセレクト市場に上場し、国内外の市場に事業を展開しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
JJSF vs PCRX — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $343.8M | $177.4M |
| 純利益 | $883.0K | $2.9M |
| 粗利率 | 27.9% | — |
| 営業利益率 | 0.2% | 3.9% |
| 純利益率 | 0.3% | 1.6% |
| 売上前年比 | -5.2% | 5.0% |
| 純利益前年比 | -82.8% | — |
| EPS（希薄化後） | $0.05 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $177.4M | ||
| Q4 25 | $343.8M | $196.9M | ||
| Q3 25 | $410.2M | $179.5M | ||
| Q2 25 | $454.3M | $181.1M | ||
| Q1 25 | $356.1M | $168.9M | ||
| Q4 24 | $362.6M | $187.3M | ||
| Q3 24 | $426.8M | $168.6M | ||
| Q2 24 | $440.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $883.0K | — | ||
| Q3 25 | $11.4M | $5.4M | ||
| Q2 25 | $44.2M | $-4.8M | ||
| Q1 25 | $4.8M | $4.8M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $29.6M | $-143.5M | ||
| Q2 24 | $36.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 27.9% | 79.5% | ||
| Q3 25 | 31.7% | 80.9% | ||
| Q2 25 | 33.0% | 77.4% | ||
| Q1 25 | 26.9% | 79.7% | ||
| Q4 24 | 25.9% | 78.7% | ||
| Q3 24 | 31.8% | 76.9% | ||
| Q2 24 | 33.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 0.2% | 1.2% | ||
| Q3 25 | 2.8% | 3.5% | ||
| Q2 25 | 13.3% | 4.7% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 1.7% | 13.2% | ||
| Q3 24 | 9.3% | -82.8% | ||
| Q2 24 | 11.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 9.7% | -2.7% | ||
| Q1 25 | 1.4% | 2.8% | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 6.9% | -85.1% | ||
| Q2 24 | 8.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.05 | $0.05 | ||
| Q3 25 | $0.59 | $0.12 | ||
| Q2 25 | $2.26 | $-0.11 | ||
| Q1 25 | $0.25 | $0.10 | ||
| Q4 24 | $0.26 | $0.38 | ||
| Q3 24 | $1.52 | $-3.11 | ||
| Q2 24 | $1.87 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $66.8M | $144.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $912.9M | $653.9M |
| 総資産 | $1.3B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $144.3M | ||
| Q4 25 | $66.8M | $238.4M | ||
| Q3 25 | $105.9M | $246.3M | ||
| Q2 25 | $77.4M | $445.9M | ||
| Q1 25 | $48.5M | $493.6M | ||
| Q4 24 | $73.6M | $484.6M | ||
| Q3 24 | $73.4M | $453.8M | ||
| Q2 24 | $64.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $912.9M | $693.1M | ||
| Q3 25 | $966.7M | $727.2M | ||
| Q2 25 | $969.9M | $757.8M | ||
| Q1 25 | $935.0M | $798.5M | ||
| Q4 24 | $946.8M | $778.3M | ||
| Q3 24 | $957.0M | $749.6M | ||
| Q2 24 | $937.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $36.0M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $17.0M | — |
| FCFマージンFCF / 売上 | 4.9% | — |
| 設備投資強度設備投資 / 売上 | 5.5% | — |
| キャッシュ転換率営業CF / 純利益 | 40.73× | — |
| 直近12ヶ月FCF直近4四半期 | $83.1M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $43.7M | ||
| Q3 25 | $66.4M | $60.8M | ||
| Q2 25 | $51.2M | $12.0M | ||
| Q1 25 | $12.3M | $35.5M | ||
| Q4 24 | $35.2M | $33.1M | ||
| Q3 24 | $46.3M | $53.9M | ||
| Q2 24 | $65.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $17.0M | $43.5M | ||
| Q3 25 | $44.8M | $57.0M | ||
| Q2 25 | $28.5M | $9.3M | ||
| Q1 25 | $-7.2M | $26.9M | ||
| Q4 24 | $16.1M | $31.0M | ||
| Q3 24 | $29.1M | $49.8M | ||
| Q2 24 | $45.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 22.1% | ||
| Q3 25 | 10.9% | 31.7% | ||
| Q2 25 | 6.3% | 5.1% | ||
| Q1 25 | -2.0% | 15.9% | ||
| Q4 24 | 4.4% | 16.6% | ||
| Q3 24 | 6.8% | 29.6% | ||
| Q2 24 | 10.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.5% | 0.1% | ||
| Q3 25 | 5.3% | 2.2% | ||
| Q2 25 | 5.0% | 1.5% | ||
| Q1 25 | 5.5% | 5.1% | ||
| Q4 24 | 5.3% | 1.1% | ||
| Q3 24 | 4.0% | 2.4% | ||
| Q2 24 | 4.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 40.73× | — | ||
| Q3 25 | 5.84× | 11.20× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 2.55× | 7.37× | ||
| Q4 24 | 6.84× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.79× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
JJSF
| Food Service | $219.2M | 64% |
| Frozen Beverages | $78.7M | 23% |
| Repair And Maintenance Service | $22.5M | 7% |
| Other | $12.7M | 4% |
| Machine Sales | $10.7M | 3% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
